CommercialCoverageHigh impact
Endovascular Repair of Aortic Diseases (CPB 0651, reviewed 2026-04-24)
Aetna·Cardiothoracic Surgery, Vascular Surgery, Radiology +2 more·Medical Policy
Effective date
Apr 24, 2026
We identified it
Aug 14, 2026
Summary
Aetna has updated its Clinical Policy Bulletin 0651 (effective 2026-04-24) clarifying coverage for endovascular repair of aortic diseases, including specific FDA-approved procedures for infrarenal abdominal aortic aneurysms, descending thoracic aortic aneurysms, aortic coarctation, and pulmonary artery stenosis/hypoplasia. The policy also designates certain procedures as experimental/investigational (e.g., Nellix device, GORE EXCLUDER thoraco-abdominal branch endoprosthesis, total endovascular aortic arch repair), which will not be covered. Billing teams must verify procedure eligibility and device FDA approval status before claim submission.
Action Required
Immediately (before 2026-04-24): Billing team must review all pending and future endovascular aortic repair claims to verify FDA-approved device usage and appropriate CPT codes (33880-33904, 34701-34848). Update billing system to flag claims using experimental devices (Nellix, GORE EXCLUDER thoraco-abdominal branch endoprosthesis, bifurcated-bifurcated repairs, aortic arch repairs, fabric/mesh wrapping) for denial without prior authorization review. Providers must document device FDA-approval status and medical necessity on all operative reports. Add pre-billing checklist to EMR requiring confirmation of: (1) FDA-approved device used, (2) correct anatomical indication (infrarenal AAA, descending thoracic AAA, aortic coarctation ≥1.5 kg with HTN and pressure gradient >20 mmHg, or pediatric pulmonary artery stenosis), and (3) applicable CPT code selection. For surveillance imaging post-endovascular repair, reference EviCore Peripheral Vascular Disease and Pediatric PVD Imaging Guidelines. Claims submitted with non-FDA-approved devices or experimental procedures will be denied.